Rapid Communication - Gynecology and Reproductive Endocrinology (2023) Volume 7, Issue 1

New endometriosis cellular atlas offers a better understanding of the condition

Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, New Haven, USA

*Corresponding Author:

Linda Giudine
Department of Obstetrics
Gynecology and Reproductive Sciences
Yale School of Medicine, New Haven, USA
E-mail: michaelmureller@ucsf.edu

Received: 08-Jan-2023, Manuscript No. AAGGS-23-87703; Editor assigned: 10-Jan-2023, PreQC No. AAGGS-23-87703(PQ); Reviewed: 23-Jan-2023, QC No. AAGGS-22-87703; Revised: 25-Jan-2023, Manuscript No. AAGGS-23-87703 (R); Published: 31-Jan-2023, DOI:10.35841/2591-7994-7.1.135

Citation: Giudine L. New endometriosis cellular atlas offers a better understanding of the condition. Gynecol Reprod Endocrinol. 2023;7(1):135

Introduction

Endometriosis is a condition where the wrong place has cells that resemble the uterine lining. Endometriosis is typically located on the lining of the pelvic cavity or in the ovaries, but in exceedingly rare cases, it can also be found in places further away, such the lungs (thoracic endometriosis). Endometriosis lesions can bleed, grow, and even invade neighbouring organs, just like the uterus can. This leads to a variety of problems, such as infertility and persistent, frequently incapacitating discomfort. Additionally, systemic symptoms like gastrointestinal issues and greater pain sensitivity are typically experienced by patients. Endometriosis research has been hampered by a lack of funding [1]. Despite being extremely prevalent and disproportionately affecting women, endometriosis is one of the most underfunded diseases. There are a number of reasons for this, including societal perceptions of issues that only impact women and the lack of attention endometriosis has received from a medical, social, and political standpoint.

It's important to remember that while though most endometriosis patients identify as women and have uteruses, transgender men and people without uteruses (due to hysterectomy or a congenital condition, for example) can also be impacted. We must incorporate these patient populations into our study in a critical way. Endometriosis is often treated with medications that lower oestrogen levels in the body, hence slowing the growth of lesions (such as combination oral contraceptives, or "The Pill"). Patients regularly utilise analgesics to help them manage their pain. However, therapy frequently produces unfavourable side effects for patients, or the medication eventually stops working. Suppressing the lesions is not compatible with pregnancy and often does not boost fertility because the underlying reason is still there. For the purpose of removing or burning lesions, some people undergo surgical treatment. Recurrence is common, though, and over 50% of patients who have surgery also have subsequent treatments [2].

It's crucial to realise that endometriosis requires years to fully recover from. Comprehensive approaches to care, which may include (as needed) cognitive behavioural therapy, mindfulness-based therapy, and physical therapy for pelvic floor dysfunction, are likely to produce the best results for patients. Many medical professionals recommend a healthy diet, good sleep hygiene, and exercise to manage life with endometriosis.

Guidelines for both diagnosis and treatment

This molecular atlas will advance research toward earlier endometriosis diagnosis, subtype differentiation, a better comprehension of the overlap with ovarian cancer in a small but significant percentage of endometriosis patients, and insights into the potential development of molecularly targeted endometriosis therapy. Researchers found that the immune system behaves differently in endometriosis cells than in healthy cells. The illness might be successfully treated with new immunotherapy treatments [3].

Recent research suggests that by altering the immune system's reaction to lesions, we may be able to treat endometriosis. This is particularly interesting since immune treatments that are being used to treat other diseases may be quickly adapted to treat endometriosis. There is still a need for additional investigation [4]. Endometriomas that were superficial as opposed to deeply penetrating displayed extremely distinct cellular characteristics. The following stage would be in vitro research to see how specific endometriosis cell types respond to present hormone therapies. For the many people who suffer from this crippling ailment, the mapping of endometriosis by this research has identified possible diagnostic and therapeutic paths for exploration [5].

References

1. Petraglia F, Hornung D, Seitz C, et al. Reduced pelvic pain in women with endometriosis: Efficacy of long-term dienogest treatment. Arch Gynecol Obstet. 2012;285(1):167-73.

Indexed at, Google Scholar, Cross Ref

2. Streuli I, de Ziegler D, Santulli P, et al. An update on the pharmacological management of endometriosis. Expert Opin Pharmacother. 2013;14(3):291-305.

Indexed at, Google Scholar, Cross Ref

3. Busacca M, Riparini J, Somigliana E, et al. Postsurgical ovarian failure after laparoscopic excision of bilateral endometriomas. Am J Obstet Gynecol. 2006;195(2):421-5.

Indexed at, Google Scholar, Cross Ref

4. Parker JD, Leondires M, Sinaii N, et al. Persistence of dysmenorrhea and nonmenstrual pain after optimal endometriosis surgery may indicate adenomyosis. Fertil Steril. 2006;86(3):711-5.

Indexed at, Google Scholar, Cross Ref

5. Harb HM, Gallos ID, Chu J, et al. The effect of endometriosis on in vitro fertilisation outcome: A systematic review and meta‐analysis. BJOG. 2013;120(11):1308-20.

Indexed at, Google Scholar, Cross Ref